Abstract:Abstract Background Gut microbiota plays a key role in the development of sarcopenia via the ‘gut‐muscle’ axis, and probiotics‐based therapy might be a strategy for sarcopenia. Fecal microbiota transplantation from young donors (yFMT) has attracted much attention because of its probiotic function. However, whether or not yFMT is effective for sarcopenia in old recipients is largely unknown. Thus, we aimed to investigate the effect and mechanism of yFMT on age‐related sarcopenia. Methods The fecal microbiota of either young (12 weeks) or old (88 weeks) donor rats was transplanted into aged recipient rats for 8 weeks. Then, muscle mass, muscle strength, muscle function, muscle atrophy, and muscle regeneration capacity were measured. Analysis of fecal 16 s rRNA, serum non‐targeted metabolomic, gut barrier integrity, and muscle transcriptome was conducted to elucidate the interaction between gut microbiota and skeletal muscles. Results As evaluated by magnetic resonance imaging examination, grip strength test (P < 0.01), rotarod test (P < 0.05), and exhaustive running test (P < 0.05), we found that yFMT mitigated muscle mass loss, muscle strength weakness, and muscle function impairment in aged rats. yFMT also countered age‐related atrophy and poor regeneration capacity in fast‐ and slow‐switch muscles, which were manifested by the decrease in slow‐switch myofibres (both P < 0.01) and muscle interstitial fibrosis (both P < 0.05) and the increase in the cross‐section area of myofibres (both P < 0.001), fast‐switch myofibres (both P < 0.01), and muscle satellite cells (both P < 0.001). In addition, yFMT ameliorated age‐related dysbiosis of gut microbiota and metabolites by promoting the production of beneficial bacteria and metabolites—Akkermansia, Lactococcus, Lactobacillus, γ‐glutamyltyrosine, 3R‐hydroxy‐butanoic acid, and methoxyacetic acid and inhibiting the production of deleterious bacteria and metabolites—Family_XIII_AD3011_group, Collinsella, indoxyl sulfate, indole‐3‐carboxilic acid‐O‐sulphate, and trimethylamine N‐oxide. Also, yFMT prevented age‐related destruction of gut barrier integrity by increasing the density of goblet cells (P < 0.0001) and the expression levels of mucin‐2 (P < 0.0001) and tight junctional proteins (all P < 0.05). Meanwhile, yFMT attenuated age‐related impairment of mitochondrial biogenesis and function in fast‐ and slow‐switch muscles. Correlation analysis revealed that yFMT‐induced alterations of gut microbiota and metabolites might be closely related to mitochondria‐related genes and sarcopenia‐related phenotypes. Conclusions yFMT could reshape the dysbiosis of gut microbiota and metabolites, maintain gut barrier integrity, and improve muscle mitochondrial dysfunction, eventually alleviating sarcopenia in aged rats. yFMT might be a new therapeutic strategy for age‐related sarcopenia.

Age-related gut microbiota transplantation disrupts myocardial energy homeostasis and induces oxidative damage

Aged microbiota exacerbates cardiac failure by PPARα/PGC1α pathway

Aged Gut Microbiome Induces Metabolic Impairment and Hallmarks of Vascular and Intestinal Aging in Young Mice

Aged gut microbiota contribute to different changes in antioxidant defense in the heart and liver after transfer to germ-free mice

Aged gut microbiota promotes arrhythmia susceptibility via oxidative stress

The brain-protective mechanism of fecal microbiota transplantation from young donor mice in the natural aging process via exosome, gut microbiota, and metabolomics analyses

Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain

Impact of gut microbiota on cardiac aging

Abstract 4140993: Time-Restricted Feeding Alleviates Cardiac Aging Through Gut Microbiota

Su2006 – Fusobacterium Nucleatum May Promote Glycolysis Via Modulating Lncrna in Colorectal Cancer Cells

Does Young Feces Make the Elderly Live Better? Application of Fecal Microbiota Transplantation in Healthy Aging

Gut microbiota remodeling improves natural aging-related disorders through Akkermansia muciniphila and its derived acetic acid

Faecal Microbiota Transplantation from Young Rats Attenuates Age‐related Sarcopenia Revealed by Multiomics Analysis

Role of the Gut Microbiota in Glucose Metabolism During Heart Failure

Age-Related Changes in the Gut Microbiota Promote Atrial Fibrillation

Decreased Enterobacteriaceae translocation due to gut microbiota remodeling mediates the alleviation of premature aging by a high‐fat diet

Gut microbiota drives age-related oxidative stress and mitochondrial damage in microglia via the metabolite N6-carboxymethyllysine

Age-related shifts in gut microbiota contribute to cognitive decline in aged rats

Divergent age-associated and metabolism-associated gut microbiome signatures modulate cardiovascular disease risk

Targeting gut microbiota in aging-related cardiovascular dysfunction: focus on the mechanisms

Research on the anti-aging mechanisms of Panax ginseng extract in mice: a gut microbiome and metabolomics approach